{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:20:30Z","timestamp":1779312030582,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jval.2020.12.001","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T21:15:51Z","timestamp":1610572551000},"page":"196-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare Beneficiaries"],"prefix":"10.1016","volume":"24","author":[{"given":"Lili","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandipan","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Kent","family":"Kwoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Tighe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary M.","family":"Reisfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Slack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie L.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Hsuan","family":"Lo-Ciganic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2020.12.001_bib1","series-title":"Micromedex\u00ae2.0, (electronic version)","year":"2019"},{"key":"10.1016\/j.jval.2020.12.001_bib2","unstructured":"Drugs@fda. FDA approved drug products."},{"key":"10.1016\/j.jval.2020.12.001_bib3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","article-title":"Gabapentinoid use in the United States 2002 through 2015","volume":"178","author":"Johansen","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jval.2020.12.001_bib4","first-page":"83","article-title":"Trends, patient and prescriber characteristics in gabapentinoid use in a sample of United States ambulatory care visits from 2003 to 2016","volume":"9","author":"Zhou","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jval.2020.12.001_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain - is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2020.12.001_bib6","series-title":"Medicines use and spending in the U.S. \u2014 a review of 2016 and outlook to 2021","year":"2017"},{"key":"10.1016\/j.jval.2020.12.001_bib7","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1377\/hlthaff.2011.0370","article-title":"False claims act prosecution did not deter off-label drug use in the case of neurontin","volume":"30","author":"Kesselheim","year":"2011","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jval.2020.12.001_bib8","first-page":"559","article-title":"Examination of the evidence for off-label use of gabapentin","volume":"9","author":"Mack","year":"2003","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.jval.2020.12.001_bib9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians","volume":"166","author":"Radley","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jval.2020.12.001_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002369","article-title":"Benefits and safety of gabapentinoids in chronic low back pain: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Shanthanna","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.jval.2020.12.001_bib11","doi-asserted-by":"crossref","first-page":"E786","DOI":"10.1503\/cmaj.171333","article-title":"Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis","volume":"190","author":"Enke","year":"2018","journal-title":"CMAJ"},{"key":"10.1016\/j.jval.2020.12.001_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nrrheum.2014.47","article-title":"Osteoarthritis pain: nociceptive or neuropathic?","volume":"10","author":"Thakur","year":"2014","journal-title":"Nature Rev Rheumatol"},{"key":"10.1016\/j.jval.2020.12.001_bib13","doi-asserted-by":"crossref","first-page":"E668","DOI":"10.1097\/BRS.0b013e318241e5de","article-title":"The burden of chronic low back pain: clinical comorbidities, treatment patterns, and health care costs in usual care settings","volume":"37","author":"Gore","year":"2012","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1016\/j.jval.2020.12.001_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1477-7525-9-71","article-title":"The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States","volume":"9","author":"Schaefer","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2020.12.001_bib15","first-page":"23","article-title":"Health care costs in us patients with and without a diagnosis of osteoarthritis","volume":"5","author":"Le","year":"2012","journal-title":"J\u00a0Pain Res"},{"key":"10.1016\/j.jval.2020.12.001_bib16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jdiacomp.2014.10.013","article-title":"Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy","volume":"29","author":"Sadosky","year":"2015","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.jval.2020.12.001_bib17","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","article-title":"How addictive are gabapentin and pregabalin? A systematic review","volume":"27","author":"Bonnet","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jval.2020.12.001_bib18","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.jval.2020.12.001_bib19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1176\/appi.ajp.2014.14101272","article-title":"Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky","volume":"172","author":"Smith","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jval.2020.12.001_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.01.013","article-title":"Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment\u2013A nation-wide register-based open cohort study","volume":"174","author":"Abrahamsson","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jval.2020.12.001_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.jval.2020.12.001_bib22","doi-asserted-by":"crossref","first-page":"732","DOI":"10.7326\/M18-1136","article-title":"Pregabalin and the risk for opioid-related death: a nested case\u2013control study","volume":"169","author":"Gomes","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2020.12.001_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40264-017-0595-1","article-title":"All-cause and drug-related medical events associated with overuse of gabapentin and\/or opioid medications: a retrospective cohort analysis of a commercially insured us population","volume":"41","author":"Peckham","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.jval.2020.12.001_bib24","article-title":"Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among Medicare beneficiaries in the United States: a retrospective cohort study [e-pub ahead of print]","author":"Zhou","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.jval.2020.12.001_bib25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"67","year":"2019","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jval.2020.12.001_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13075-015-0530-8","article-title":"Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia","volume":"17","author":"Kim","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jval.2020.12.001_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/CLEP.S105613","article-title":"Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US","volume":"9","author":"Mues","year":"2017","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.jval.2020.12.001_bib28","series-title":"CCW Medicare adminstrative data user guide","year":"2019"},{"key":"10.1016\/j.jval.2020.12.001_bib31","first-page":"447","article-title":"Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans","volume":"16","author":"Margolis","year":"2010","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jval.2020.12.001_bib32","first-page":"113","article-title":"Clinical guidelines for the use of chronic\u00a0opioid therapy in chronic noncancer pain","volume":"10","author":"Chou","year":"2009","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.jval.2020.12.001_bib33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1533-2500.2008.00204.x","volume":"8","author":"Pergolizzi","year":"2008","journal-title":"Pain Pract"},{"key":"10.1016\/j.jval.2020.12.001_bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.eplepsyres.2017.11.022","article-title":"An update on the prevalence and incidence of epilepsy among older adults","volume":"139","author":"Ip","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jval.2020.12.001_bib35","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.2105\/AJPH.2009.180646","article-title":"Age and gender trends in long-term opioid analgesic use for noncancer pain","volume":"100","author":"Campbell","year":"2010","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jval.2020.12.001_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-152-2-201001190-00006","article-title":"Opioid prescriptions for chronic pain and overdose: a cohort study","volume":"152","author":"Dunn","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2020.12.001_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0968","article-title":"Evaluation of machine-learning algorithms for predicting opioid overdose risk among medicare beneficiaries with opioid prescriptions","volume":"2","author":"Lo-Ciganic","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jval.2020.12.001_bib39","unstructured":"Pharmacy Quality Alliance. PQA opioid core measure set-2019."},{"key":"10.1016\/j.jval.2020.12.001_bib42","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jama.2017.21897","article-title":"Gabapentin approvals, off-label use, and lessons for postmarketing evaluation efforts","volume":"319","author":"Wallach","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2020.12.001_bib43","doi-asserted-by":"crossref","DOI":"10.1177\/0049124113503141","article-title":"A\u00a0note on a Stata plugin for estimating group-based trajectory models","author":"Jones","year":"2013","journal-title":"Sociol Methods Res"},{"key":"10.1016\/j.jval.2020.12.001_bib44","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jclinepi.2012.04.010","article-title":"Classifying developmental trajectories over time should be done with great caution: a comparison between methods","volume":"65","author":"Twisk","year":"2012","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jval.2020.12.001_bib45","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1177\/0962280216673085","article-title":"Group-based multi-trajectory modeling","volume":"27","author":"Nagin","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jval.2020.12.001_bib46","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/0049124106292364","article-title":"Advances in group-based trajectory modeling and an sas procedure for estimating them","volume":"35","author":"Jones","year":"2007","journal-title":"Sociol Methods Res"},{"key":"10.1016\/j.jval.2020.12.001_bib47","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/add.13270","article-title":"Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization","volume":"111","author":"Lo-Ciganic","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.jval.2020.12.001_bib48","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s11606-016-3747-6","article-title":"Trajectories of diabetes medication adherence and hospitalization risk: a retrospective cohort study in a large state Medicaid program","volume":"31","author":"Lo-Ciganic","year":"2016","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.jval.2020.12.001_bib49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","article-title":"Group-based trajectory modeling in clinical research","volume":"6","author":"Nagin","year":"2010","journal-title":"Annu Rev Clin Psychol"},{"key":"10.1016\/j.jval.2020.12.001_bib50","unstructured":"US Bureau of Labor Statistics. Consumer price index."},{"key":"10.1016\/j.jval.2020.12.001_bib51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMsa1514387","article-title":"State legal restrictions and prescription-opioid use among disabled adults","volume":"375","author":"Meara","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2020.12.001_bib52","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/papr.12585","article-title":"Healthcare costs and medication adherence among patients with fibromyalgia: combination medication vs duloxetine, milnacipran, venlafaxine, and pregabalin initiators","volume":"18","author":"Marlow","year":"2018","journal-title":"Pain Pract"},{"key":"10.1016\/j.jval.2020.12.001_bib53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.jval.2020.12.001_bib54","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpainsymman.2006.11.013","article-title":"Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial","volume":"34","author":"Keskinbora","year":"2007","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jval.2020.12.001_bib55","first-page":"695","article-title":"Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements?","volume":"23","author":"Shinde","year":"2015","journal-title":"Support Care Cancer"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520345332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520345332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:22:52Z","timestamp":1761096172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520345332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1098301520345332"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.12.001","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare Beneficiaries","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}